Osimertinib Resistance and EGFR Mutations in NSCLC Treatment
The presence of the T790M mutation during first or second-generation EGFR-TKI treatments is observed in 50-60% of patients. This mutation ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
